Therapeutic strategies and controversies in the treatment of multiple myeloma.
This is a general overview on the treatment of multiple myeloma (MM) with particular emphasis on controversial aspects. The importance of avoiding treatment for asymptomatic patients is emphasized. The selection of initial treatment (melphalan/prednisone vs. combination chemotherapy) is summarized. The duration of initial treatment, the role of interferon maintenance, as well as the treatment of resistant myeloma patients are critically reviewed. Finally, the treatment of particular subsets of myeloma patients (i.e., young patients, elderly people, patients presenting with renal failure) is discussed.
Bladé
J
J
Department of Hematology, University of Barcelona, Spain.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D011241:Prednisone / Q000627:therapeutic use
D007372:Interferons; D008558:Melphalan; D011241:Prednisone